VJVirtual | Treatment of KIT exon 9-mutated GISTs

Robin Jones, MD, The Royal Marsden Hospital, London, UK, talks on a retrospective study on the biology and treatment of KIT exon 9 mutations in gastrointestinal stromal tumors (GISTs), including the investigation of 131 patients who harbor a KIT exon 9 mutation receiving a starting dose of either 800mg or 400mg imatinib per day. No significant difference was found between the survival outcomes of patients receiving either starting dose.